Advicenne to update about the market access of Sibnayal® in Great Britain. Sibnayal® is a combination of potassium citrate and potassium bicarbonate. Sibnayal® has been accepted for use within NHS Scotland.

This positive decision by the Scottish Medicines Consortium (SMC) makes Sibnayal® immediately available to all Scottish distal Renal Tubular Acidosis (dRTA) patients as per the licensed indication. This decision validates the medical contribution of Sibnayal® and its favorable cost/benefit ratio in treating dRTA. In England, Advicenne has withdrawn its submission to the National Institute for Health and Care Excellence (NICE).

The current absence of long-term outcome data for dRTA patients precluded a robust health economic model to be provided to NICE. Therefore, in England, Advicenne will work directly with specialist centers to make Sibnayal® available to treat dRTA patients. Advicenne believes that the economic impact of this decision will be limited given the limited number of prescribers and hospitals requiring local access to Sibnayal®.

In addition, Advicenne, within the framework of the European registry of patients suffering from dRTA, plans to collect data that will support a new submission to the NICE and provide the necessary long-term outcomes data.